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Abstract: Congestive heart failure (CHF) is the main cause of acute dyspnea in patients presented to an emergency department 
(ED), and it is associated with high morbidity and mortality. B-type natriuretic peptide (BNP) is a polypeptide, released by 
ventricular myocytes directly proportional to wall tension, for lowering renin-angiotensin-aldosterone activation. For 
diagnosing CHF, both BNP and the biologically inactive NT-proBNP have similar accuracy. Threshold values are higher in 
elderly population, and in patients with renal dysfunction. They might have also a prognostic value. Studies demonstrated 
that the use of BNP or NT-proBNP in dyspneic patients early in the ED reduced the time to discharge, total treatment cost. 
BNP and NT-proBNP should be available in every ED 24 hours a day, because literature strongly suggests the beneﬁ  cial 
impact of an early appropriate diagnosis and treatment in dyspneic patients.
Etiologic diagnosis of febrile patients who present to an ED is complex and sometimes difﬁ  cult. However, new evidence 
showed that there are interventions (including early appropriate antibiotics), which could reduce mortality rate in patients 
with sepsis. For diagnosing sepsis, procalcitonin (PCT) is more accurate than C-reactive protein. Thus, because of its excel-
lent speciﬁ  city and positive predictive value, an elevated PCT concentration (higher than 0.5 ng/mL) indicates ongoing and 
potentially severe systemic infection, which needs early antibiotics (e.g. meningitis). In lower respiratory tract infections, 
CAP or COPD exacerbation, PCT guidance reduced total antibiotic exposure and/or antibiotic treatment duration.
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Introduction
The number of emergency department (ED) admissions continues to climb, with a limited number of 
departments available to handle the volume (McCaig and Burt, 2004). The rapid and accurate diagnosis 
of the most severe patients is a routine challenge for emergency physicians. Unfortunately in patients 
suspect of sepsis, symptoms and clinical signs, and current routine laboratory tests lack both sensitivity 
and speciﬁ  city in correctly identifying which patients have sepsis and need antibiotics (Hausfater et al. 
2002). Likewise, the signs and symptoms of congestive heart failure (CHF) are frequently nonspeciﬁ  c, 
highly variable especially in older adults or patients with pre-existing respiratory diseases (Rihal et al. 
1995; Lien et al. 2002; Mueller et al. 2005a). Indeed, CHF can present with wheezing and mimic acute 
asthma, so-called cardiac asthma (Jorge et al. 2007). However, new evidences show that early appropri-
ate interventions can reduce mortality rate in patients with sepsis and improve outcome in acute dyspnea 
(Rivers et al. 2001; Mueller et al. 2004). Rivers et al. demonstrated a 16% decrease in 28-day mortality 
rate by simply implementing a protocol mandating aggressive ED resuscitation during the ﬁ  rst 6 hrs of 
a patient’s ED visit. Likewise, studies suggested that an early appropriate diagnosis and therapy is asso-
ciated with a decreased mortality from acute dyspnea/CHF (Fig. 1) (Ray et al. 2006a). Thus, available 
biological tools—namely biomarkers—that could provide a rapid diagnosis of bacterial infection in case 
of fever/sepsis and rapid diagnosis of CHF in case of dyspnea could be very useful (Maisel et al. 2002; 
Mueller et al. 2004; Jones et al. 2007). Furthermore, their ability to accurately assess a patient’s disease 
severity and mortality risk at ED presentation could be also important (Meisner, 2005). The ideal bio-
marker would be readily available, technically easy to perform with a quick turn-around time, inexpen-
sive, highly speciﬁ  c, very sensitive, and preferably highly correlated in quantitative terms with disease 204
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severity. Such a test would provide early diagnostic 
accuracy, prognostic information, and indicate 
responsiveness to treatment interventions. Regret-
tably no such ideal biomarker exists at present. 
However, the purpose of this review is to indicate 
recent developments in biomarkers of sepsis and 
heart failure to evaluate their impact on clinical use 
in the emergency setting. Thus, we will focus on 
the rationale, and use of B natriuretic peptides (NP) 
in CHF and procalcitonin (PCT) in sepsis in 
adults.
Role of the Natriuretic Peptides 
in Heart Failure
Physiologic secretion of natriuretic 
peptides (NPs)
An important pathophysiologic mechanism in 
cardiovascular disease is the imbalance between 
the vasoconstrictive/antinatriuretic action of some 
neuroendocrine factors (de Bold et al. 1981; 
Clerico et al. 2006). Cardiac endocrine function 
is an essential component of the homeostatic 
regulation network, including the renin-
angiotensin-aldosterone system, vasopressin, 
endothelins, and sympathetic nervous system, and 
the counter-regulatory vasodilatory/natriuretic 
response, mainly represented by NP (Yasue et al. 
1994). As cardiac performance decreases, all 
neurohormonal systems are progressively 
stimulated in an attempt to sustain cardiac output 
and circulatory homeostasis. However, the activa-
tion of neurohumoral mechanisms may worsen 
the hemodynamics, and have direct adverse 
effects on myocardial function, and stimulate the 
NPs (Levin et al. 1998).
The NP have several physiologic actions 
(Fig. 2), the most important being (a) vasodilation; 
(b) promotion of natriuresis and diuresis; (c) inhi-
bition of the sympathetic nervous system and of 
the renin-angiotensin-aldosterone system, endo-
thelins, cytokines, and vasopressin; (d) inhibition 
of the pathophysiologic mechanisms responsible 
for ventricular and vascular hypertrophy and 
remodeling; and (e) beneﬁ  cial effects on endothe-
lial dysfunction secondary to the atherosclerotic 
process, including blunting of shear stress and 
regulation of coagulation and ﬁ  brinolysis, as well 
as inhibition of platelet activation (Levin et al. 
1998; Maisel, 2003).
The NP family includes atrial natriuretic peptide 
(ANP), B-type natriuretic peptide (BNP) and its 
related peptide, whereas C-type natriuretic peptide 
(CNP) and urodilatin (DNP) are predominantly 
secreted by noncardiac tissues (endothelium and 
kidney, respectively) (Ruskoaho, 2003).
BNP derives from the precursor pre-proBNP, 
containing 134 amino acids and including a signal 
peptide of 26 amino acids. ProBNP, produced by 
cleavage of the signal peptide, is further split into 
BNP, which is considered to be the biologically 
active hormone, and an inactive N-amino terminal 
fragment, NT-proBNP (Fig. 3). NT-proBNP is used 
in a commercial analytical method and refers to 
measurement of N-terminal 1–76 fragment. BNP 
is a 32-aa polypeptide containing a 17-aa ring 
structure common to all NP (Maisel et al. 2002). 
BNP gene expression is a feature of both atrial and 
ventricular myocytes. In the healthy heart, BNP 
gene expression occurs mainly in the atria. How-
ever, ventricular BNP gene expression is up-regu-
lated in diseases that affect the ventricles, such as 
CHF, which suggests that it may be a more speciﬁ  c 
indicator of ventricular disorders than other NP. It 
is a well-established fact that atrial myocytes con-
tain secretory granules for peptide storage, which 
led to the primary hypothesis about the endocrine 
heart (Levin et al. 1998). Importantly, atrial gran-
ules store both intact proBNP and cleaved products, 
i.e. bioactive BNP-32. In contrast, ventricular myo-
cytes in the healthy heart do not seem to produce 
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Figure 1. Effects of an appropriate (black bars) or inappropriate 
(white bars) initial diagnosis in the emergency department on 
prognosis (used with permission from Ray et al. 2006a).205
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these granules, and do not contain proBNP-derived 
peptides. The nucleic acid sequence of the BNP 
gene contains the destabilizing sequence “TATT-
TAT,” which suggests that turnover of BNP mes-
senger RNA is high and that BNP is synthesized 
in bursts. This release appears to be directly pro-
portional to ventricular volume expansion and 
pressure overload (Levin et al. 1998).
The clearance of the two peptides is different 
(Anand-Srivastava, 2005). BNP is cleared by 
several mechanisms, including the kidneys, speciﬁ  c 
clearance receptor-mediated degradation (natruretic 
peptide receptor type C, NPR-C) and enzymatic 
degradation, especially neutral endopeptidase. In 
contrast, NT-proBNP seems to be removed 
exclusively by the kidneys (Austin et al. 2006). 
These differences in clearances are responsible for 
the fact that BNP has a lower absolute plasma 
concentration and a lower half-life. However, Kroll 
et al. recently re-calculated the NT-proBNP half-
life and found that it was closer to that of BNP 
(25 minutes) (Kroll et al. 2007).
Factors related to natriuretic peptide 
secretions
NP production are greatly increased in diseases 
characterized by an expanded ﬂ  uid volume, includ-
ing renal failure, liver cirrhosis, and CHF (Clerico 
et al. 1998). The circulating concentrations of NPs 
are also modiﬁ  ed by several physiologic factors, 
such as circadian variations, sodium intake, and 
drugs (including corticosteroids, diuretics, 
angiotensin-converting enzyme inhibitors, and 
adrenergic agonists and antagonists). However, the 
main variations in circulating concentrations of 
NPs in healthy adults are related to weight, aging 
and gender. In particular, the BNP concentration 
is about one third higher in women than in men at 
age 50 years (Emdin et al. 2003). The higher NPs 
values in women could be explained by the phys-
iologic stimulation of female sex steroid hormones. 
The increases in NPs with aging may be also 
attributable to physiologic cardiac hypertrophy and 
kidney’s senescence (Loke et al. 2003). Moreover, 
the increase in NPs with aging may be attributable 
Figure 2. Physiologic actions of BNP.
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to a decrease in their clearance rate (Ray et al. 
2006a). When adjusted for relevant covariates, 
compared with normal counterparts, overweight 
and obese patients with acute CHF have lower 
circulating NT-proBNP and BNP levels, suggesting 
a BMI (body mass index)-related defect in natri-
uretic peptide secretion (Das et al. 2005). However, 
a recent study suggested that the association 
between BMI and BNP and NT-proBNP could be 
mediated by lean mass rather than fat mass (Das 
et al. 2005), and these results do not support the 
hypothesis that the lower BNP levels seen in 
obesity are driven by enhanced BNP clearance 
mediated via NPR-C. In fact, studies on effect of 
obesity on natriuretic peptides are controversial 
(Hermann-Arnhof et al. 2005).
There is a strong inter-relationship between heart 
failure (therefore BNP and NT-proBNP concentra-
tions) and renal function. Therefore, the central 
questions are i) how to interpret BNP and NT-
proBNP concentrations in patients with renal 
impairment; ii) is BNP superior to NT-proBNP in 
case of renal dysfunction? Januzzi et al. found that 
NT-proBNP and eGFR (glomerular ﬁ  ltration rate) 
were inversely and independently related 
(Anwaruddin et al. 2006). McCullough et al. deter-
mined that BNP concentrations and cut-off points 
were inﬂ  uenced by renal function, particularly in 
those with an eGFR (glomerular ﬁ  ltration rate) less 
than 60 mL/min/1.73 m² (McCullough et al. 2003). 
Chenevier-Gobeaux et al. showed that (i) both 
NT-proBNP and BNP values were inversely cor-
related to eGFR, and (ii) the lower was the eGFR, 
the higher were the cut-off values of NT-proBNP 
and BNP (Chenevier-Gobeaux et al. 2005). Con-
versely, Ray et al. demonstrated that BNP was more 
accurate than NT-proBNP in elderly patients, 
because of a decrease in creatinine clearance (Ray 
et al. 2005).
Their diagnostic role in dyspnea
BNP is an independent predictor of high left 
ventricular end-diastolic pressure, or high 
capillary pulmonary artery pressure (Maeda et al. 
1998). Both correlate to the New York Heart 
Figure 3.
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Association classiﬁ  cation, the severity of the heart 
failure and inversely correlate to left ventricular 
ejection fraction (Davis et al. 1994; Januzzi et al. 
2005). Cardiologic studies showed that BNP and 
NT-proBNP can reliably predict the presence or 
absence of left ventricular dysfunction on echocar-
diogram (Lubien et al. 2002).
The potential clinical usefulness of BNP and 
NT-proBNP for differential diagnosis of dyspnea 
and for prognostic stratiﬁ  cation of patients with 
CHF has been conﬁ  rmed in the last 5 years. Thus, 
the Task Force of the European Society of 
Cardiology recommended that a NPs assay should 
be included in the ﬁ  rst step of the algorithm for the 
diagnosis of HF as electrocardiography (ECG) and 
chest x-rays (Swedberg et al. 2005).
Acute dyspnea is the key symptom of most 
respiratory diseases, with high related morbidity 
and mortality (Ray et al. 2006a). Unfortunately, 
emergency physicians’ accuracy to diagnose CHF 
is less than 60%–70% (McCullough et al. 2003; 
Ray et al. 2006a). In the EPIDASA study (Ray 
et al. 2006a), 514 patients older than 65 years 
with acute dyspnea were included. The in-hospital 
mortality was 16%, with a higher mortality 
(21%) in the 219 (42%) patients with CHF. An 
inappropriate emergency treatment occurred in 
162 (32%) patients, and led to a higher mortality 
(25% versus 11%; p  0.001), highlighting the 
importance of an early correct diagnosis and 
treatment in the ED (Fig. 1).
Numerous studies evaluated and validated both 
NPs to diagnose CHF in acute dyspnea in adults 
patients (Davis et al. 1994; Cabanes et al. 2001; 
Dao et al. 2001; Logeart et al. 2002; Maisel 
et al. 2002; Lainchbury et al. 2003; Bayes-Genis 
et al. 2004; Ray et al. 2004; Alibay et al. 2005; 
Chenevier-Gobeaux et al. 2005; Januzzi et al. 2005; 
Mueller et al. 2005b; Ray et al. 2005; Berdague 
et al. 2006). The largest studies were performed by 
Maisel et al. with BNP (Maisel et al. 2002) and 
Januzzi et al. (Januzzi et al. 2005) with NT-proBNP. 
All these studies used the same methodology: there 
were prospective studies of consecutive patients 
who came to EDs with acute dyspnea and whose 
BNP/NT-proBNP was measured—blindly—at 
admission (Maisel et al. 2002). The clinical 
diagnosis of CHF was adjudicated by independent 
experts, who were blinded to the results of the 
BNP/NT-proBNP assay, according to the summary 
chart and echocardiographic findings; usual 
exclusion criteria were severe renal insufﬁ  ciency, 
patients whose dyspnea was clearly not secondary 
to CHF (chest trauma), and dyspnea secondary to 
severe coronary ischemia.
In the Maisel’s study, BNP levels by themselves 
were more accurate than any historical or physical 
ﬁ  ndings or laboratory values in identifying CHF 
as the cause of dyspnea. The diagnostic accuracy 
of BNP at a cutoff of 100 pg/ml was 83.4% with 
an area under the receiver-operating-characteristic 
curve (AUC) of 0.91; and BNP was more accurate 
(83%) than the Framingham criteria (73%), a 
commonly used set of criteria for diagnosing 
CHF. In fact, the analysis of their ROC curve 
reveals that the best threshold value which should 
have been deﬁ  ned by the highest accuracy of 84% 
was close to 150 pg/ml (with a lower sensitivity 
of 85%).
The PRIDE (ProBNP Investigation of Dyspnea 
in the Emergency Department) study included 600 
patients (mean age of 67 years) (Januzzi et al. 
2005). A NT-proBNP level 300 pg/ml was opti-
mal for ruling out CHF, with a negative predictive 
value of 99%. Again, NT-proBNP testing alone 
was superior to clinical judgment alone for diag-
nosing acute CHF (p = 0.006). Using an age 
categorization of 50 years (n = 144) and 50 
years (n = 455), they determined that—for ruling 
in acute CHF—the optimal cut off were 450 and 
900 pg/ml with areas under the curve of 0.98 and 
0.93, respectively. However, the major criticism 
was the use of 2 different cut-off depending of the 
age of the population studied.
Speciﬁ  c considerations in elderly
To our knowledge, only 3 studies speciﬁ  cally have 
evaluated BNP and NT-proBNP in elderly patients 
(Ray et al. 2004; Arques et al. 2005; Berdague et al. 
2006). Ray et al. included 314 patients with acute 
dyspnea. They demonstrated that increased BNP 
was the strongest independent predictor of a ﬁ  nal 
diagnosis of CHF (odds ratio (OR) 24.4, p  0.001), 
and the accuracy of BNP-assisted diagnosis was 
higher than that of the emergency physician (0.84 
versus 0.77, p  0.05). They also showed that, 
whatever the empirical probability for CHF (from 
absent to very likely), estimated by the emergency 
physician, an elevated level of BNP higher than 
250 pg/ml was an accurate marker of CHF (posi-
tive likelihood ratio from 5.9 to 8.8, respectively). 
Berdague et al. assessed the usefulness of NT-
proBNP assay for the diagnosis of CHF in 256 208
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elderly patients (mean age 81 years). The diagnoses 
made in the ED were incorrect or uncertain in 45% 
of cases. NT-proBNP 2000 pg/ml was the most 
powerful independent marker of cardiac dyspnea 
(OR 13.6, p  0.001). Lastly, Arques et al. dem-
onstrated that BNP had an AUC of 0.875 for pre-
dicting CHF with preserved LV systolic function 
(Arques et al. 2005). Overall in the elderly, BNP 
and NT-proBNP are both accurate to diagnose 
CHF. However, threshold values are higher.
Roughly, CHF appears to be highly unlikely 
below a BNP plasma concentration of 100 pg/ml, 
or a NT-proBNP below 500 pg/mL, and CHF 
appears to be likely when plasma concentration of 
BNP is higher than 500 pg/ml, or NT-proBNP is 
greater 2000 pg/mL (Fig. 4). Between these 
situations (so-called “the grey zone”), further 
investigation are needed (such as echocardiogra-
phy, CT chest..., since many causes might be 
suspected (including atrial ﬁ  brillation without 
CHF, pulmonary embolism, exacerbation of COPD 
(chronic obstructive respiratory disease), severe 
pneumonia, severe sepsis and CHF) (Ray et al. 
2004; Knudsen et al. 2005; Maeder et al. 2006).
Comparison between BNP 
and NT-proBNP
In most of the studies, BNP and NT-proBNP were 
well correlated (Alibay et al. 2004; Clerico et al. 
Figure 4. Diagnostic strategy based on B natriuretic peptide levels in elderly patients admitted for ARF in the emergency department.
1In the grey zone (BNP between 100 and 500 pg/mL) which represents less than a quarter of patients, further investigations are needed, and 
ER physicians should consider massive PE, severe exacerbation of COPD or severe pneumonia as possible diagnoses…
2Emergency physicians should be keep in mind that half of elderly patients with ARF has more than one, i.e. a BNP greater than 500 pg/ml 
strongly suggests CHF, but other diagnosis could have precipitated CHF.
3For NT-proBNP, the cut-off values are 500 and 2,000 pg/mL.
Abbreviation: CXR: chest x- ray; EKG: Electrocardiogram; ABG: arterial blood gas analysis; CHF: congestive heart failure; ACS: acute 
coronary syndrome, CT: computed tomography; IV: intra-venous; NIV: non invasive ventilation including continuous positive airway pressure; 
ACEi: angiotensin converting enzyme inhibitor; EC: echocardiography.
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2006; Lainchbury et al. 2003; Ray et al. 2005). 
Whether BNP has a better accuracy than NT-proBNP 
has been a matter of debate. Ray et al. included 202 
patients (mean age of 80 years) in whom 88 (44%) 
had CHF. For diagnosing CHF, the AUC for NT-
proBNP was lower than that of BNP (0.80 vs. 0.85, 
p  0.05). Using logistic regression, only the 
diagnosis of CHF predicted the elevation of BNP 
greater than 250 pg/mL (OR = 27.7, p  0.001). 
Conversely, beside the diagnosis of CHF (OR = 11.7, 
p  0.001), a creatinine clearance of less than 
60 mL/min (OR = 2.7; p  0.05) independently 
predicted the elevation of NT-proBNP greater than 
1,500 pg/mL. It might be the renal dysfunction 
partly explained the lower accuracy of NT-proBNP 
observed, because in contrast to BNP, renal excretion 
is a major route of elimination of NT-proBNP (Ray 
et al. 2005).
However, the other studies compared diagnostic 
accuracy of BNP and NT-proBNP, even in an 
elderly population, and did not conﬁ  rm this previ-
ous ﬁ  ndings. In a subgroup (n = 75) analysis of their 
study, Berdague et al. demonstrated that AUC was 
0.86 for BNP compared with 0.88 for NT-proBNP 
(p = 0.6) (Berdague et al. 2006). In 160 patients 
over 75 years of age, Alibay et al. demonstrated 
that the diagnostic value was similar for BNP and 
NT-proBNP (AUC of 0.82 vs. 0.84, respectively) 
(Alibay et al. 2004). Mueller et al. demonstrated 
that AUC for BNP and NT-proBNP in patients with 
dyspnoea did not differ signiﬁ  cantly (AUC of 0.916 
vs. 0.903) (Mueller T et al. 2005). Chenevier-
Gobeaux et al. found that NT-proBNP and BNP 
concentrations increased in a similar way when 
eGFR decreased in 381 patients (mean age of 79 
years) with dyspnoea (Chenevier-Gobeaux et al. 
2005). NT-proBNP (and BNP) cut-off points rose 
as a function of eGFR categories: from 1360 (and 
290) pg/ml in patients with eGFR 60–89 ml/min/
1.73 m
2, to 6550 (and 515) pg/ml in patients with 
eGFR 15–29 ml/min/1.73 m
2.
Overall BNP and NT-proBNP might be equally 
useful as an aid in the diagnosis of CHF in patients 
presenting to the ED with shortness of breath.
Do NT-proBNP and BNP improve 
outcome?
There is now evidence that early measurement of 
BNP or NT-proBNP following admission to the ED 
could improve the outcome of dyspneic patients. 
Mueller et al. conducted a prospective, randomized, 
controlled study of 452 patients who presented to 
the ED with acute dyspnea: 225 patients were ran-
domly assigned to a diagnostic strategy involving 
the measurement of BNP levels with the use of a 
rapid bedside assay, and 227 were assessed in a 
standard manner (Fig. 4). The use of BNP levels 
reduced the need for hospitalization (75% vs 85%). 
Patients in the BNP group spent less time in the 
hospital (8 vs. 11 days), and their care cost was less 
($5410 vs. $7264) than those whose physicians used 
conventional assessment. The respective 30-day 
mortality rates were unchanged. However, a sig-
niﬁ  cant reduction in 30-day mortality was observed 
(9% in the BNP group vs. 17% in the control group; 
p = 0.039) in the sub-group of patients older than 
70 years (Mueller et al. 2004). Although echocar-
diography and pulmonary function testing were 
strongly recommended for patients, the percentage 
actually having the tests was not reported (Mueller 
et al. 2004).
Moe et al. also demonstrated that NT-proBNP 
testing improves the management of patients present-
ing with dyspnea (Moe et al. 2007). Knowledge of 
NT-proBNP results reduced the number of patients 
rehospitalized over 60 days by 35% (51% to 33%), 
and direct medical costs of all ED visits, hospitaliza-
tions, and subsequent outpatient services (US $6129 
to US $5180 per patient) over 60 days from enroll-
ment. However, knowledge of NT-proBNP results 
did not result in any major improvement in clinical 
outcomes to 60 days, including lack of signiﬁ  cant 
differences in the initial rate of hospitalization, hos-
pital length of stay, or mortality rates.
Other potential uses of natriuretic 
peptides assessment in acute 
dyspnea
Studies suggest that high BNP or NT-proBNP level 
at admission could be of prognostic importance 
(Harrison et al. 2002; Logeart et al. 2004; Bayes-
Genis et al. 2005; Gegenhuber et al. 2006; Januzzi 
et al. 2006).
Januzzi et al. demonstrated that NT-proBNP at 
the time of presentation was not only diagnostically 
useful, but also strongly predicted likelihood for 
short-term mortality in subjects with CHF, with a 
more than ﬁ  ve-fold increase in risk for death by 76 
days among those with marked elevation in NT-
proBNP concentrations (Januzzi et al. 2006). 
Gegenhuber et al. followed up 251 consecutive 
patients (mean age of 72 years) admitted for 210
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shortness of breath (Gegenhuber et al. 2006). 
Mortality was higher in patients with baseline BNP 
and NT-proBNP concentrations above cut off levels. 
In a multivariate analysis of the EPIDASA study, 
elevated NT-proBNP or BNP (odds ratio 2.06) was 
also predictive of death (Ray et al. 2006a). However, 
other studies suggest that BNP or NT-proBNP val-
ues at predischarge rather than at admission, could 
be more accurate for predicting long-term outcome 
in patients admitted for acute CHF. Furthermore, 
changes in BNP levels during acute cares is also of 
interest (Logeart et al. 2004). Logeart et al. included 
114 patients with severely decompensated CHF. 
They found that mean BNP levels were 1,015 pg/ml 
at admission, 881 ± 615 ng/l at 24 h, 638 pg/ml at 
48 h, and 457 pg/ml predischarge. Recently, Chenevier-
Gobeaux et al. reported that NT-proBNP higher than 
3,855 pg/ml at admission was associated with higher 
in-hospital mortality in 324 patients aged 75 years 
and over admitted for dyspnea (17.9% vs. 9.7%, 
Fig. 5) (Chenevier-Gobeaux et al. 2007).
Prognostic value in pulmonary 
embolism
Like in acute coronary syndrome (Morrow et al. 
2005), studies have suggested that BNP or 
NT-pro-BNP (as cardiac Troponin) were accurate 
in risk stratiﬁ  cation for PE in a middle-aged popu-
lation and had a high positive predictive value for 
in-hospital death (Binder et al. 2005; Pieralli et al. 
2006; Logeart et al. 2007). However, a study 
evaluated the usefulness of BNP in risk stratiﬁ  cation 
of PE in 51 patients older than 65 years (79 ± 9 
years) patients. Although, the median BNP level 
was signiﬁ  cantly higher in the group of complicated 
PE (274 pg/mL vs. 78 pg/mL, p  0.05), BNP was 
not a solid test to identify patients with a risk of 
complicated PE in elderly patients (AUC of only 
0.72, p  0.05) (Ray et al. 2006b). Thus, in clini-
cal practice the measurement of BNP or NT-
proBNP level for each PE admitted to an ED 
cannot be recommended.
NP in practice
BNP and NT-proBNP have similar accuracy in 
acute dyspnea to diagnose CHF, even in elderly 
or “renal” patients. They probably have a prog-
nostic value. Use of BNP or NT-proBNP should 
be promoted in the ED to assist in triage (CHF or 
not). Thus, their measurements should be strongly 
promoted in ED, especially when the cause of 
dyspnea in uncertain in order to improve costs and 
morbidity.
Role of the PCT in Case of Fever 
or Suspicion of Sepsis
Introduction about PCT and CRP
Among several markers of inﬂ  ammation and sep-
sis, PCT and C-reactive protein (CRP) markers 
are being studied to investigate their accuracy for 
the diagnosis of bacterial infections. PCT is the 
prehormone of calcitonin, which is normally 
secreted by the C cells of the thyroid in response 
to hypercalcemia; under these normal conditions, 
negligible serum PCT concentrations are detected 
(Muller et al. 2000). The mechanism proposed for 
PCT production after inﬂ  ammation and its role 
are still not completely known. It is believed that 
PCT is produced by the liver and other organs 
(adipocytes, lungs, muscles cells) (Spapen et al. 
2006) and peripheral blood mononuclear cells, 
modulated by lipopolysaccharides and sepsis-
related cytokines (Tumor Necrosis Factor α, IL-2, 
IL-6). PCT secretion begins within 4 h after 
stimulation and peaks at 8 h, clearing when the 
insult is under control (Harbarth et al. 2001). PCT 
levels are therefore very low (0.05 ng/ml) in 
healthy humans. However, during severe infec-
tions (especially bacterial) with systemic mani-
festations PCT levels increase to over 100 ng/ml. 
Remarkably, the large amounts of PCT produced 
Figure 5. Kaplan-Meier curves showing survival according to 
NT-proBNP (from Chenevier-Gobeaux with permission (Chenevier-
Gobeaux et al. 2007)).
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during infections do not lead to an increase in 
plasma calcitonin levels or activity. In contrast to 
the short half-life of calcitonin (10 min), PCT has 
a long half-life of approximately 22–35 h in 
serum. During severe systemic infections PCT is 
probably produced by extrathyroid tissues. Thus, 
patients who have previously undergone total 
thyroidectomy can still produce high levels of PCT 
during a severe infectious episode. PCT is stable 
in samples, the assay is relatively easy to perform, 
with a moderate cost (∼$15), and the result is 
available within 1/2 h.
CRP is an acute-phase reactant, and CRP level 
measurements are frequently used to aid in the 
diagnosis of bacterial infections. CRP is 
synthesized by the liver, mainly in response to 
IL-6, which is produced not only during infection 
but also in many types of inﬂ  ammation (Clyne 
and Olshaker, 1999). It binds to polysaccharides 
in pathogens, activating the classical complement 
pathway. CRP secretion starts within 6 h 
after stimulation, peaking only after 36 h. The 
assay for determing CRP levels is easy to 
perform, often automated, quick and has a lower 
cost (∼$5).
Why do we need a biomarker 
of sepsis in our EDs?
Etiologic diagnosis of febrile patients who present 
to an ED is complex and sometimes difﬁ  cult. Phy-
sicians have to identify and often rapidly treat 
patients with systemic bacterial infection. However, 
the empirical use of broad-spectrum antibiotics in 
patients without infection is potentially harmful, 
facilitating colonization and superinfection with 
multidrug resistant bacteria. Most microbiological 
test (blood cultures) results are not available for 
24 h. Clinical signs of SIRS (systemic inﬂ  ammation 
response syndrome) including changes in body 
temperature, tachycardia, and leukocytosis are 
neither sensitive enough nor speciﬁ  c enough for the 
diagnosis of sepsis and can often be misleading. 
Although CRP level is a very sensitive marker of 
inﬂ  ammation, it lacks speciﬁ  city and so has limited 
utility in the ED. Trauma, burns, pancreatitis, major 
surgery, and many other conditions may elicit 
clinical signs of SIRS in the absence of microbial 
infection. There is no gold standard for diagnosing 
sepsis, as cultures may be negative especially in 
cases of antibiotic pre-treatment or inadequate 
sampling. Indeed, more than 30% of infected 
patients remain without clear documentation of 
microbial infection. Among 2,154 septic shock 
patients only 50% of patients received effective 
antimicrobial therapy within 6 hrs of documented 
hypotension. The multivariate analysis revealed 
that time to initiation of effective antimicrobial 
therapy was the single strongest predictor of out-
come. Furthermore, each hour of delay in antimi-
crobial administration over the ensuing 6 hrs was 
associated with an average decrease in survival of 
7.6% (Kumar et al. 2006). Although its speciﬁ  city 
and sensitivity are poor, serum lactate is used for 
diagnosing septic shock (Levy et al. 2003). Lactate 
could be a biologically plausible candidate for risk-
stratiﬁ  cation biomarkers in ED patients with infec-
tion (Shapiro et al. 2005).
However, among the potentially useful markers 
of sepsis, PCT has been suggested to be the most 
promising, although results are variable depending 
on the severity of illness and patient population 
studied.
Overall results in ICU and internal 
medicine
Three recent meta-analysis reported conﬂ  ict results 
in ICU or in ED. Jones et al. found the diagnostic 
performance of the PCT test for identifying bacte-
remia in ED patients to be moderate, with an AUC 
of 0.84 and a sensitivity and speciﬁ  city of 76% and 
70%, respectively (Jones et al. 2007). Uzzan et al. 
found that global odds ratios for diagnosis of infec-
tion complicated by systemic inﬂ  ammation were 
15.7 using PCT and 5.4 using CRP. The AUC for 
PCT was better than for CRP (0.78 vs. 0.71, 
p = 0.02) (Uzzan et al. 2006). Lastly, Tang et al. 
found that PCT had a low diagnostic performance 
in differentiating sepsis from SIRS in critically ill 
adult patients, with an AUC of 0.79, a positive 
likelihood ratio 3.03, and a negative likelihood 
ratio 0.43 (Tang et al. 2007).
Actually, we need to keep in mind that PCT is 
potentially a biomarker of a state or syndrome 
(SIRS/sepsis/severe sepsis) not an indicator of a 
disease (unlike BNP which is a biomarker of a 
disease: CHF). A recent study nicely summarized 
the complexity of the evaluation and potential 
usefulness of PCT. Gaini et al. included 194 
patients admitted in an internal medicine depart-
ment; with suspected community-acquired 
infections and sepsis (Gaini et al. 2006); 106 had 
either infection or sepsis. They compared accuracy 212
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of Lipopolysaccharide-binding protein (LBP, an 
acute-phase protein that has been suggested as a 
marker of infection, because this protein has a role 
in the innate immune response in binding to lipo-
polysaccharide), PCT, CRP, and IL-6 (which has 
a central role in inducing the synthesis of acute-
phase proteins such as CRP, PCT and LBP). In a 
ROC curve analysis to distinguish between non-
infected patients and infected patients, CRP and 
IL-6 had the highest AUC values of 0.83 and 0.82, 
compared to 0.77 for PCT. In a ROC analysis to 
distinguish between patients with noninfectious 
SIRS and patients with sepsis/severe sepsis, 
IL-6, LBP and CRP had an AUC of 0.87, 0.86 and 
0.84, respectively; compared to 0.75 for PCT. 
However, in a ROC analysis to distinguish between 
patients with sepsis and patients with severe sepsis, 
PCT performed best with an AUC of 0.74. We 
could explain these conﬂ  icting results by the higher 
accuracy of PCT as a prognostic indicator but not 
as a diagnostic biomarker. As authors stated “CRP, 
IL-6 and LBP appear to be superior to PCT as 
diagnostic markers for infection and sepsis in 
patients. PCT appears to be superior as a severity 
marker”. This study also highlighted that biomark-
ers examined could have different test qualities 
depending on the study population. Other reports 
suggested that PCT could have a prognosis value 
in ICU or ED (Hausfater et al. 2002). For example, 
Clec’h et al. included 75 patients with suspicion 
of sepsis in an ICU (Clec’h et al. 2006). A cutoff 
value of 6 ng/mL on day 1, separated patients who 
died from those who survived with 87.5% sensitiv-
ity and 45% speciﬁ  city. CRP was not helpful for 
predicting mortality.
In emergency medicine medical literature is 
poorer than in critical care (Luzzani et al. 2003; 
Simon et al. 2004) and also leads to conﬂ  ict results.
Evaluation of procalcitonin in ED
Hausfater et al. prospectively evaluated serum PCT 
concentrations in patients who presented to an ED 
with suspected infectious or inﬂ  ammatory disease 
(criteria of inclusion: order of CRP by EP). Of 195 
study patients, 68 (30%) had ﬁ  nal diagnosis of 
systemic infection, and 24 of those 68 had elevated 
serum PCT levels (0.5 ng/mL). The PCT level 
had a sensitivity of 0.35 and speciﬁ  city of 0.99 for 
the diagnosis of systemic infection. In multivariate 
analysis, the PCT level was the only independent 
variable associated with this diagnosis (OR 43.5; 
p = 0 .0004); in contrast, the CRP level was not. 
The AUC of PCT for discrimination between 
patients with and without infection was 0.79 
(Hausfater et al. 2002). Guven et al. included 34 
patients with signs of SIRS and found that 
predictive accuracy for sepsis expressed as AUC 
was 0.88 for PCT, 0.44 for WBC, and 0.34 for CRP 
(p  0.05) (Guven et al. 2002).
However, Chan et al. found that PCT was not 
a better marker of bacterial infection than CRP 
for adult ED patients, but was a useful marker of 
the severity of infection. Compared with CRP, 
PCT had a comparable sensitivity (69.5% versus 
67.2%), a lower speciﬁ  city (64.6% versus 93.9%), 
and a lower AUC (0.689 versus 0.879). However 
PCT levels, but not CRP levels, were signiﬁ  cantly 
higher in bacteremic and septic shock patients. 
Multivariate logistic regression identiﬁ  ed that a 
PCT level 2.6 ng/ml was independently associ-
ated with the development of septic shock (OR, 
38.3) (Chan et al. 2004). Indino et al. also reported 
poor results with PCT (cutoff point of 0.5 ng/ml) 
for the diagnosis of a systemic infection in ED 
patients (on whom 57% had a ﬁ  nal diagnosis of 
systemic infection), with a sensitivity of 0.57, a 
speciﬁ  city of 0.85 (Indino et al. 2007).
In 208 elderly patients aged 75 and older 
admitted to an acute geriatric care unit, Strucker 
et al. found that PCT had good speciﬁ  city (94%), 
but very low sensitivity (24%) in detecting infec-
tion (Stucker et al. 2005). One of the explanations 
is that they used a less sensitive test (Liaison 
BRAHMS PCT, limit of quantiﬁ  cation 0.3 ng/mL). 
However, Caterino, also found that in elder ED 
patients, AUC for PCT for bacteremia was low 
as 0.70 (Caterino et al. 2004). Recently, Hausfater 
et al. included (Hausfater et al. 2007), in a pro-
spective, monocentric non interventional study, 
243 patients with body temperature 38.5 C. PCT 
assay with a 0.2 mg/L cutoff value had a sensitiv-
ity of 0.77 and a speciﬁ  city of 0.59 for the diag-
nosis of bacterial/parasitic infection. Furthermore, 
51% of the patients with PCT 5 mg/L had 
critical illness (death and/or ICU admission) in 
comparison with 13% of the patients with lower 
PCT values.
Because of the low sensitivity but excellent 
speciﬁ  city and positive predictive value for this 
test, an elevated PCT concentration (higher than 
0.5 ng/mL) indicates ongoing and potentially 
severe systemic infection with an increased risk of 
fatal outcome, whereas normal values do not 213
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exclude the possibility of an infectious process in 
its beginning stages (Fig. 5).
Evaluation of PCT in speciﬁ  c diseases
Accuracy of PCT to distinguish 
bacterial from aseptic meningitis
In patients with suspected meningitis and a positive 
Gram staining of the cerebrospinal ﬂ  uid, the diag-
nosis of bacterial meningitis (BM) is proven. Further 
tests are not necessary, and empirical antibiotic 
treatment should be started immediately. However, 
in 30% to 40% of cases, the Gram-stained smear 
shows no bacteria. Thus, as recommended, patients 
in whom BM cannot be completely ruled out usually 
receive empirical antibiotic treatment until the 
microbiological findings or the clinical course 
excludes a bacterial origin. However, the cost of 
antibiotic therapy and its attendant hospitalization, 
as well as its potential adverse effects, have raised 
concern about giving unnecessary antibiotics in 
cases of nonbacterial meningitis (NBM). In adults, 
4 studies evaluated PCT in meningitis. In 1999, 
Viallon et al. suggested that PCT had a higher diag-
nostic sensitivity (100%) and speciﬁ  city (100%) 
than that of CRP to determine the BM origin of 
meningitis (Viallon et al. 1999). Jereb et al. evalu-
ated the diagnostic performance of serum PCT 
levels in 45 adult patients (Jereb et al. 2001). 
Medical History andphysical 
findings:
Suspicion of sepsis
Bacterial or viral infection  or 
inflammatory process?
Obvious diagnosisof infection:
CAP, BM, pyelonephritis…
Clinical criteria of severity1
No needfor PCT
PCT
Possible sepsis 
Bacterial sepsis unlikely
No need for Antibiotics  
Bacterial sepsis very likely 
Antibiotics are needed
PCT>5 ng/mL: worseoutcome? 
0.2 < PCT < 0.5 PCT <0.20 ng /mL PCT >0.5 ng/mL 
Reevaluate clinical signs and 
PCT at 24 hours
May probably be evaluated as
an outpatient 
Figure 6. Suggested diagnostic strategy based on PCT levels in EDs.
1Systolic Blood Pressure less than 90 mmHg, mottling, oliguria, lactate 2 mmol/L or other signs of septic shock or trouble CSF after lumbar 
puncture, obvious clinical presentation of community-acquired pneumoniae (thoracic symptoms, fever, and consolidation on chest x-ray).214
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A serum PCT level 0.5 ng/ml had a positive 
predictive value for BM of 100% and a negative 
predictive value of 93%. In 151 adults with con-
ﬁ  rmed meningitis admitted to our ED, we conﬁ  rmed 
that PCT was a high predictor of BM (AUC of 0.99) 
compared to 0.75 for CRP ( p  0.05), with a best 
threshold value of 2.13 ng/mL (Ray et al. 2007). 
Schwarz et al. included a total of 30 patients with a 
mean age of 52 yrs, having acute BM (n = 16) or 
NBM (n = 14) (Schwarz et al. 2000). PCT was the 
variable with the highest speciﬁ  city for BM (100%), 
but there were false-negative ﬁ  ndings in ﬁ  ve patients 
with BM (a sensitivity of 69%). Persistently elevated 
or increasing PCT levels after 2 days were associated 
with an unfavorable clinical course. Recently, Vial-
lon et al. conﬁ  rmed that a signiﬁ  cant and early 
decrease in serum PCT concentration was associated 
with favorable cure of BM (Viallon et al. 2005).
PCT and community-acquired 
pneumonia
As much as 75% of all antibiotic doses are 
prescribed for acute respiratory tract infections 
(Prat et al. 2006). In a pilot study, Hedlund et al. 
(Hedlund and Hansson, 2000) suggested that PCT 
might aid the physician to differentiate typical 
bacterial community-acquired pneumoniae 
(CAP) etiology from atypical etiology: 8/9 
patients with pneumonia caused by atypical 
agents had PCT levels 0.5 ng/ml compared with 
6/27 patients with pneumonia caused by classic 
bacterial pathogens, mainly Streptococcus pneu-
moniae (p = 0.03). Mueller et al. included 545 
patients with suspected lower respiratory tract 
infection, admitted to the ED (Muller et al. 2007). 
PCT had a higher diagnostic accuracy (AUC: 
0.88) in differentiating CAP from other diagnoses, 
as compared to CRP (AUC: 0.76; p  0.001) and 
total leukocyte count (AUC: 0.69; p  0.001). 
PCT levels increased with increasing severity of 
CAP, classified according to the pneumonia 
severity index score (p  0.001). To determine 
the prognostic role of PCT for severe CAP, 
110 patients admitted in an ICU were prospectively 
studied. Boussekey et al. found that initial PCT 
level was signiﬁ  cantly higher in patients who 
died during the ICU stay (5.6 ng/ml vs 1.5 ng/ml; 
p  0.0001) (Boussekey et al. 2005). Christ-Cain 
and Mueller nicely performed three randomized 
studies to assess if a PCT-based therapeutic strat-
egy (based on serum PCT concentrations as 
follows: antibiotic strongly discouraged when 
less than 0.1 ng/mL; discouraged when less than 
0.25 ng/mL; encouraged when greater than 
0.25 ng/mL; strongly encouraged when greater 
than 0.5 ng/mL) could reduce antibiotic use in 
lower respiratory tract infections (Christ-Crain 
et al. 2004). The use of PCT reduced the antibi-
otic use in lower respiratory tract infections/CAP 
and COPD exacerbation (Christ-Crain et al. 
2006; Stolz et al. 2007). For example, in a ran-
domized intervention trial, 302 consecutive 
patients with suspected CAP were included. PCT 
guidance reduced total antibiotic exposure 
(relative risk, 0.52; p  0.001), antibiotic pre-
scriptions on admission (85% vs. 99%; p  0.001), 
and antibiotic treatment duration (median, 5 vs. 
12 d; p  0.001) compared with patients without 
PCT (Christ-Crain et al. 2006). Stolz et al. 
evaluated the efficacy and safety of PCT 
guidance compared to standard therapy with 
antibiotic prescriptions in patients experiencing 
exacerbations of COPD. PCT guidance reduced 
antibiotic prescription (40% vs. 72%, respec-
tively; p  0.0001) and antibiotic exposure 
(relative risk, 0.56; p  0.0001) compared to 
standard therapy (Christ-Crain et al. 2006; Stolz 
et al. 2007).
Role of PCT in various infectious 
diseases in adults
Viallon et al. demonstrated that serum PCT level 
may become a useful marker for the diagnosis of 
spontaneous bacterial peritonitis in 61 cirrhotic 
patients (cut-off value of 0.75 ng/ml, with a sen-
sitivity of 95%, a speciﬁ  city of 98%) (Viallon 
et al. 2000). However, Spahr et al. did not conﬁ  rm 
this encouraging result (Spahr et al. 2001). 
Lemiale et al. found that a single PCT level was 
a poor predictor of 28-d adverse medical out-
comes in women with pyelonephritis treated in 
the ED (Lemiale et al. 2007). Whether, PCT could 
be used and has the same diagnostic value in 
neutropenic and immunosupprssed febrile adult 
patients was suggested, but needs conﬁ  rmation 
(Bernard et al. 1998; Ortega et al. 2004; Hausfater 
et al. 2007; Massaro et al. 2007).
Discussion about conﬂ  icting results 
on procalcitonin
Differences in results in adult medical literature 
could be explain by: criteria of inclusion (fever, 215
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sepsis, SIRS…), population studied and prevalence 
of sepsis (ED, ICU, elderly patients), sample of 
patients, and primary end-points (accuracy to 
diagnose bacterial sepsis from inﬂ  ammation or non 
non bacterial disease, differentiation between SIRS 
from septic shock, accuracy to predict death…), 
threshold values, methods of assay (use of an 
ultrasensitive assay (sensitivity of 0.06 ng/mL) 
PCT Kryptor
® BRAHMS or PCT BioMerieux
® vs 
LUMITEST
® BRAHMS a relative insensitive 
assay vs a semi-quantitative assay PCT-Q
® 
BRAHMS.…).
However, the next important steps in assess-
ing PCT diagnostic values should be to test the 
usefulness of PCT on the outcome (antibiotic 
administration, morbidity, mortality) in a ran-
domized study as recently performed (Christ-
Crain et al. 2004).
Perspective in Biomarkers
It is beyond this article to describe all the new 
markers in cardiovascular diseases and/or in infec-
tious diseases. However, readers should know that 
new biomarkers are currently evaluated (ST2 for 
prognostication in CHF patients, blood levels of 
endotoxin to predict adverse outcomes in ICU, 
diagnosis of viral infection by interferon-alpha 
levels, triggering receptor expressed on myeloid 
cells-1-TREM- as reliable marker of infection 
during severe sepsis and pneumonia…) (Januzzi 
et al. 2007). Finally, other studies suggested that 
instead of a single marker, a combination of bio-
markers may improve diagnosis of infection 
(Kofoed et al. 2007).
Conclusion
There is evidence that BNP and NT-proBNP are 
reliably markers of CHF in acute dyspnea. Their 
prognostic values are strongly suggested. Used in 
conjunction with other clinical information, rapid 
measurement of BNP or NT-proBNP reduced time 
to discharge and total treatment cost of patients. 
Overall accuracy of PCT is higher than that of CRP 
to differentiate bacterial infections from non-bac-
terial infections. In suspected lower tract infections 
(CAP or COPD exacerbation), PCT guidance 
reduced total antibiotic exposure and antibiotic 
prescriptions on admission. PCT and B natriuretic 
peptides should be promoted in EDs to aid triage, 
and improve outcomes.
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